UK's Oxford Biomedica warns of core loss in first half, shares fall
26/03/2026 09:18
March 26 (Reuters) - Oxford Biomedica OXB.L warned of a first-half core loss on Thursday, citing planned maintenance shutdowns, and extra costs tied mainly to completing technology transfers and the integration of its newly acquired U.S. facility. Shares in the cell and gene therapy manufacturer dropped 6%. Here are some details on its results: The additional costs in H1 is principally related to the completion of adeno-associated virus and lentiviral technology transfer costs H1 costs also include the integration of its 2025 acquisition of a commercial scale viral vector manufacturing facility in Durham, North Carolina Oxford Biomedica reported operating core profit of 2.3 million pounds ($3.07 million) in 2025, versus a loss of 15.3 million pounds in 2024 The company, however, kept its financial forecast unchanged for 2026 and 2027 ($1 = 0.7490 pounds) (Reporting by Yadarisa Shabong and Neeshita Beura) ((Neeshita.Beura@thomsonreuters.com))